Anavex Life Sciences Corp (AVXL)

[BAR123]

Casavva
Phase 3 Program - Over 400 Patients Are Now Enrolled in Our Phase 3 Clinical Studies.
Open-label Study – Results of an Interim Analysis on the First 100 Patients Who Have Completed at Least 12 Months of Open-label Treatment with Simufilam Follow:
Drug Appears Safe and Well Tolerated.
Overall ADAS-Cog11 Scores Improved an Average of 1.5 Points (S.D. ± 6.6; P<0.05)
63% of the 100 Patients Showed an Improvement in ADAS-Cog11 Scores, and This Group of Patients Improved an Average of 5.6 Points (S.D. ± 3.8).
An Additional 21% of the 100 Patients Declined Less Than 5 Points on ADAS-Cog11, and This Group of Patients Declined an Average of 2.7 Points (S.D. ± 1.4).
Cognition Maintenance Study - Completion of Patient Enrollment is Expected Q4 2022.
Financial Results - Net Loss for Q2 2022 Was $19.3 Million, or $0.48 Per Share.
Cash Position - $197.2 Million of Cash and Cash Equivalents at June 30, 2022.